Rapid Micro Biosystems' Q3 revenue misses estimates, withdraws FY outlook
Overview
US life sciences automation provider's Q3 revenue grew 22% yr/yr but missed analyst expectations
Company reported record Q3 gross margin of 25%, up 16 percentage points yr/yr
Company signed definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany
Outlook
Company is withdrawing its full-year 2026 guidance due to pending acquisition by Merck KGaA
Result Drivers
SYSTEM PLACEMENTS AND VALIDATIONS - Co said Q3 revenue growth was driven by placements of seven Growth Direct systems and completion of 12 customer validations
GROSS MARGIN EXPANSION - Co attributed record Q3 gross margin of 25% to continued progress in margin expansion initiatives, including higher product and service gross margins
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $9.50 mln | $10 mln (4 Analysts) |
Q3 Loss Per Share | $0.23 | ||
Q3 Operating Expenses | $13 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Rapid Micro Biosystems, Inc. is $7.00, about 975.3% above its November 13 closing price of $0.65
Reuters Recommended Reads
Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
Nov 16 - ALX Oncology Q3 net loss per share narrows
Nov 13 - Indaptus Therapeutics Q3 net loss narrows as R&D costs fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)